| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Bankruptcy > Chapter 10 Bankrupt |
|
Advice You - Chapter 10 Bankrupt
What causes a person or individual to go bankrupt? There is one very possible reason that is usu According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ally the common explanation for bankruptcy: the person is unable to pay his debts. However, the ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ery reason as to why he is unable to pay would be another story. On the other hand, a company o lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. an organization could also go bankrupt. And just like a person or individual going bankrupt, th here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe reason behind a company’s bankruptcy could be because of its inability to pay its bills and oth d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro er financial obligations. What could be the reasons why these business groups could not pay? Th ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc re are various answers to this question. It could be due to very low profits. It could also be b easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi cause of the wrong kind of leadership in the company or organization itself. It could be because nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically of misallocation of its resources and funds. The reason could also be that there are not enough and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ clients or that the company or organization’s line of business is not catching the attention and ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi interest of consumers. When a company or organization has already filed for bankruptcy in court ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a they are then given bankruptcy protection. Bankruptcy protection provides these companies or or dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod anizations a chance to start anew. However, these groups are still given the responsibility of p cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin aying their creditors. Of course, when a company or an organization files for bankruptcy, they tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ave their minds set on restructuring. They could then use Chapter 10 bankruptcy to assist them i t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel this situation. Under Chapter 10, bankrupt companies could have the chance to reorganize and r ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust structure. However, there would be a court-appointed manager to assist the company. This court-a y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ppointed manager is also called a trustee. What this trustee does is primarily oversee the whole . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de reorganization process. The trustee would serve as the mediator between the company and the cour elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip . He would also see to it that any plans regarding the reorganization would be strictly followed tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Direct Selling: Work at Leisure To Increase Your Sales and Revenue Make Sure To Add Value 10 Power Packed Ways To Boost Your Profits
|